Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1407: mFOLFIRINOX vs gemcitabine + nab-paclitaxel for locally advanced pancreatic cancer
jRCTs031180085Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, irinotecan, fluorouracil, folinic acid, gemcitabine and 1 more in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival (proportion of 1-year survival). Started Aug 2016; status: completed.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acidgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCTs031180085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180085.